Self-reported arm and shoulder problems in breast cancer survivors in Sub-Saharan Africa: the African Breast Cancer-Disparities in Outcomes cohort study

This study was part of the African Breast Cancer-Disparities in Outcomes (ABC-DO) study, a prospective multicentric hospital-based cohort study of disparities in survival in women after a diagnosis of breast cancer. ABC-DO was conducted in Nigeria, Zambia, Uganda, Namibia and South Africa and its protocol is available elsewhere [15]. In brief, from September 2014 to early 2017, all women aged 18 and above who visited one of the participating hospitals and were suspected of having breast cancer were invited to participate. Of 2313 women recruited with suspected breast cancer, 2228 had the disease confirmed by histology, cytology or clinically. Overall, 2212 (99%) of those eligible women accepted to participate and were included in ABC-DO.

At baseline, data on women’s sociodemographic characteristics, comorbidities, breast cancer risk factors and health attitudes, knowledge and beliefs were collected via an interviewer-administered questionnaire. The woman agreed to be contacted thereafter every three months by mobile phone. MHealth technology was used for all real-time data collection and to facilitate contact with women or their next of kin every three-months, using a standardized protocol that minimized losses to follow-up [16]. At each 3-month follow-up contact, data on treatment (surgery, radiotherapy, chemotherapy, and endocrine therapy) were collected from both medical records and self-reports. The woman also answered the EORTC-QLQ-Br23 questionnaire, an internationally validated questionnaire to assess quality of life of women with breast cancer [17]. For the primary ASP outcomes, we used responses to the three questions pertaining, at each trimonthly contact, to the past week “Did you have pain in your arm or shoulder?”; “Did you have a swollen arm or hand?” and “Was it difficult to raise your arm or to move it sideways?” for information on arm or shoulder pain, arm or hand swelling and arm stiffness, respectively. Each of the three items were rated on a four-point Likert scale of “not at all”, “a little”, “quite a bit” and “very much”. In the present analysis, each ASP was considered present if rated “quite a bit” or “very much” and absent otherwise, as was previously done in other studies [5, 18, 19].

For the purpose of this analysis, all women enrolled into ABC-DO were included except those from South Africa (n = 675) because the regular follow-up at this site did not systematically ascertain ASP. Prevalent breast cancer cases (i.e. women with a previous diagnosis of breast cancer more than two years before enrolment n = 57) or who were lost to follow-up immediately after diagnosis were also excluded (n = 4), leaving 1476 women in the analysis.

Sociodemographic characteristics, tumour characteristics and type of treatment received, regardless of whether treatment was completed or not, were assessed in relation to each ASP self-reporting. These included: (1) Five population groups defined by country and ethnicity (Namibia black, Namibia non-black, Uganda, Nigeria and Zambia); (2) TNM stage at diagnosis (stage I/II, III, IV and unknown); (3) age at diagnosis (continuous, < 50 years and ≥ 50); (4) highest educational level (none or primary school, secondary or high school, university or technical degree); (5) body mass index (BMI) calculated from measured height and weight at baseline (continuous and < 25 kg/m², [25–30[ Kg/m², ≥ 30 kg/m²); (6) self-reported HIV status at baseline (positive, negative or unknown); (7) Self-reported hypertension (yes, no) at baseline based on the question “Have you ever been diagnosed with hypertension?”; (8) treatment and specific types of treatment (surgery, radiotherapy, chemotherapy, endocrine therapy) were considered as categorical time-varying variable, and we performed a Lexis expansion to take into account change in treatment status over time (prior treatment: yes/no/unknown) [20].

For each ASP, we examined time to the first report of the ASP. Follow-up started from the date of diagnosis and ended on the date of interview when the ASP was first reported, the date of death (as a competing event), the date when 4-year follow-up was reached, date of last live contact or 1st January 2020, whichever came first. Using this time scale, we calculated the cumulative incidence of each ASP, overall and stratified by study site, from time since diagnosis prior to receiving treatment.

To identify potential determinants for each ASP, we fitted Cox proportional hazards models. Crude models were fitted for all potential determinants adjusted for age as a continuous variable and stratified by study site. We used likelihood ratio tests to determine whether age, BMI, educational level and tumour stage would be better explained as continuous or categorical. For each ASP, a multivariate model was fitted mutually adjusting for the same set of covariates (i.e. age, BMI, educational level, stage at diagnosis and treatment received). These models yielded adjusted cause-specific hazard ratios (CHR) estimates which shows the relative change in the rate of ASP according to each determinant, in women who are currently alive.

To assess the robustness of the findings we conducted further analysis to estimate: (1) cumulative incidence of the first self-reported ASP stratified by type of ASP and tumour stage at diagnosis; (2) cumulative incidence using a more strict definition of ASP based on time to the first report of a specific ASP in a 12-month period when there were multiple reports of that ASP (not necessarily consecutive); for the latter analyses, cumulative incidences are reported up to three years after diagnosis to allow for a subsequent multiple report within the following 12-months (maximal follow-up 4-years). In addition, we fitted the multivariate models described above but conditional on women having survived the first 6 months after diagnosis and excluding those with metastatic disease, as these women might not have received the same treatment as less advanced cases, and might have been at higher risk of reporting ASP. Lastly, to better understand the respective impacts of breast cancer itself and treatment on occurrence of ASP, we estimated one-year cumulative incidences of self-reported ASP prior to and after starting treatment. All analyses were performed using STATA v15.1.

Of the 1476 women included in this analysis, there were 477 Namibian, 418 Ugandan, 383 Nigerian and 198 Zambian women. Table 1 presents baseline characteristics of these women. Briefly, mean age at diagnosis was 50.3 years (SD = 13.7). About half of the women had none or primary school education level (N = 657, 44.5%), and most were diagnosed with late-stage breast cancer (N = 1106, 75.0%). Concerning comorbidities, 342 (23.2%) of women were obese, 144 (9.8%) were HIV-positive and 426 (28.9%) had hypertension. Although there were important between-country disparities in treatment received, overall, 171 women (11.6%) did not receive any treatment, 928 (62.9%) received chemotherapy, 841 (57.0%) had surgery, 694 (47.0%) endocrine therapy, and 465 (31.5%) radiotherapy.

Of the 1476 women included in this analysis, 162 (11.0%) died before completing the first follow-up interview. Overall, 743 (50.3%) of the 1476 women reported at least once an ASP, 618 (41.9%) arm/shoulder pain, 516 (35.0%) arm stiffness and 319 (21.6%) arm/hand swelling (Fig. 1). Of the 238 (16.1%) women who reported having experienced two different ASP, either concomitantly or at different follow-up time points, 187 (78.6%) reported both arm/shoulder pain and arm stiffness, 33 (13.9%) reported pain and arm/hand swelling, and 18 (7.6%) reported both arm stiffness and swelling. Finally, 236 (16.0%) women reported having experienced all three ASP.

Four years after being diagnosed with breast cancer, cumulative incidences of shoulder/arm pain, stiffness and arm/hand swelling were 43.0% (95% CI 40.4–45.6), 35.8% (33.4–38.3) and 22.5% (20.4–24.8), based on 618, 516 and 319 women, respectively (Table 2). Among the 171 untreated women, these cumulative incidences were, respectively, 29.2% (21.9–36.8), 21.2% (14.7–28.4) and 15.3% (9.8–21.9) based on 47, 33 and 23 women, respectively (Additional file 1: Table S1). In comparison to prior to receiving any treatment, cumulative incidences of ASP were two to three times higher after treatment start (Additional file 2: Table S2 and Additional file 3: Fig. S1). About half of all women who reported a specific ASP had multiple reports of that ASP within a 12-months period (Additional file 4: Fig. S2). The rate at which new ASPs were reported declined over time, with half of the 4-year cumulative reporting incidence occurring within the first year of diagnosis (Additional file 4: Fig. S2).

Determinants of first self-reported ASP, separately for each ASP type, are described in detail in Table 3, and in Additional file 5: Table S3 and Additional file 6: Fig. S3. After adjusting on all potential determinants of ASP identified in crude analysis, there were important between-country and between-ethnicity disparities. Relative to Namibia black women, the risk of a first ASP self-report was lowest for non-black Namibians for all three ASP and highest for Ugandan women for all ASP (fully adjusted CHR 2.00; 95%CI 1.61–2.48 for shoulder/arm pain, 1.52 (1.21–1.90) for arm stiffness and 1.59 (1.18–2.15) for arm/hand swelling), and for Nigerian women for all ASP except arm stiffness.

Tumour stage at diagnosis was the main determinant of ASP self-reporting (Table 3 and Additional file 7: Fig. S4), with women diagnosed with a more advanced stage tumour having an increased risk of self-reporting an ASP (p for heterogeneity < 0.0001 for all three types of ASP). The strongest association was observed for arm swelling – relative to women with localized disease at diagnosis, the risk of self-reporting this ASP was two times higher (CHR 1.98; 95% CI 1.40–2.79) for women with locally advanced cancers, and four times higher (4.02; 2.59–6.23) for those with metastatic disease.

The risk of self-reporting an ASP was inversely associated with the woman’s educational level for all ASP (Table 3), being particularly marked for shoulder/arm pain and arm stiffness (p for trend < 0.0001). Relative to women with a university level, those with only primary school level or less were 94% (fully adjusted CHR 1.94; 95% CI 1.51–2.49) more likely to self-report shoulder/arm pain and 77% (1.77; 1.34–2.33) more likely to self-report arm stiffness. Older age at breast cancer diagnosis (≥ 50 years) tended to be associated with a higher reporting of shoulder/arm pain (CHR 1.18; 95% CI 0.99–1.39, p = 0.06), but there was no evidence that the risk of self-reporting any of the three ASPs depended on a woman’s BMI, HIV status or hypertension.

Receiving treatment was associated with the likelihood of reporting shoulder/arm pain (CHR 1.37; 95% CI 1.08–1.72) and arm/hand swelling (CHR 1.67; 95% CI 1.16–2.41). These associations were driven by chemotherapy, which increased the risk of reporting an ASP by about 50% for both shoulder/arm pain (CHR 1.48; 95% CI 1.21–1.82) and arm stiffness (1.48; 1.17–1.87), and by up to 65% for arm/hand swelling (1.65; 1.22–2.23). In contrast, surgery decreased the risk of reporting a shoulder/arm pain by about 25% (0.76; 0.63–0.92). However, when stratifying the analysis according to tumour stage at diagnosis, these treatment effects were only observed in women with late stage cancers (Additional file 8: Table S4).

After excluding women with metastatic cancer and conditioning the analysis on 6-month survival, results remained similar. However, receiving radiotherapy reduced the risk of reporting an arm stiffness, and this association was strongest in women diagnosed with a localized breast cancer (Additional file 8: Table S4).

Using data from a large and multi-centric cohort, we obtained robust estimates of the frequency of ASP in women after a breast cancer diagnosis across multiple SSA settings and examined their determinants. To our knowledge, our study is the first in SSA to show that ASP occur not only after receiving treatment but may also be present prior to treatment. The frequency of self-reported ASP was high in this setting, but with important between-country disparities. Overall, about 1 out of 2 women reported having experienced a moderate to severe ASP at least once during the follow-up period. Shoulder/arm pain was the most commonly reported ASP, followed by arm stiffness and arm/hand swelling, and most often, women reported multiple ASP types either concomitantly or at different follow-up time points. Among women who reported having experienced ASP, about half reported the same type of ASP more than once over time. More advanced breast cancer stage at diagnosis, older age, having a lower socioeconomic position and receiving treatment increased the risk of self-reported ASP.

Our estimates of ASP frequency in SSA were higher than those previously reported in the region, maybe due to differences in study designs, sample sizes, ASP assessment methods and follow-up durations [4, 9, 10]. There were, however, important between-country disparities in ASP reporting, with Namibian non-black women reporting ASP the least, and Ugandan women the most. These differences, which remained after controlling for the earlier stage at breast cancer diagnosis of non-Namibian black women, may reflect over- or under-reporting of ASP for cultural reasons, variations in data collection quality or in interpretation of EORTC-QLQ-Br23 questions across sites, and/or ethnic differences in a woman’s susceptibility to develop an ASP, because within Namibia, non-black women tended to report less ASP than black women. Lifestyle and treatment management and aftercare will also differ substantially.

In ABC-DO, women with lower educational level were at higher risk of self-reporting an ASP, irrespective of tumour stage at diagnosis, maybe due to lower breast cancer awareness and higher physical demands of their daily cores [11]. Women over 50 years of age tended to be at higher risk of self-reporting a shoulder/arm pain, which contrasts with the findings from a South African study in which the prevalence of ASP decreased with age [4]. Also, we did not find an association between BMI and ASP, possibly because it was only measured once, at breast cancer diagnosis, and we were not able to capture its change over time in the analysis [21].

In our study, a higher breast cancer stage at diagnosis was the most important determinant of self-reporting an ASP. In contrast to HICs where most women have an early stage diagnosis, late stage diagnosis for breast cancer is common in SSA due to low breast cancer awareness among both women and healthcare professionals, and long delays to presentation of symptomatic women to a healthcare provider, final diagnosis and treatment initiation, with disadvantaged populations being particularly affected [11, 12, 22, 23]. In our cohort, three quarters of women had a late stage breast cancer at diagnosis, with nearly half having a tumour size over five centimetres and about two thirds positive lymph nodes at diagnosis. It is plausible that, the larger tumours, and the increased number of affected lymph nodes in women with an advanced breast cancer, may have favoured ASP development, including prior to receiving treatment [24, 25].

Receiving treatment also increased the risk of reporting an ASP in women with advanced breast cancers, but our study may have lacked statistical power to detect an association in women with localized breast cancers. This association may partly be due to remaining unmeasured systematic differences between women who underwent specific treatment types and those who did not. The treatment effect was driven by chemotherapy, while surgery was associated with lower self-reporting of shoulder/arm pain, in line with what was found in another South African study with similar cohort characteristics [4]. Indeed, in our study, chemotherapy was the first treatment given and its initiation may have preceded the first follow-up interview. Women who received chemotherapy had higher SEP indicators and higher stage at diagnosis than women who did not. While chemotherapy is usually administered through central lines in HICs, these are not available in most LMICs where peripheral intravenous perfusions are used instead, as in our cohort. It is therefore possible that chemotherapy drugs administered through a peripheral line engender side-effects such as local inflammation and ASP. However, our study was not designed to assess treatment effects and thus we cannot exclude the possibility that the observed chemotherapy-ASP association may be due to local symptoms caused by the breast cancer itself [26, 27]. Despite the more invasive surgical procedures often used in SSA, as compared to HICs, such as mastectomy and axillary lymph node dissection, it is possible that surgical removal of large tumours or a high number of affected lymph nodes relieve pain in women with advanced disease [4, 8, 28, 29]. We also found that women diagnosed with an early stage cancer who survived at least six months had lower risk of self-reporting an ASP after receiving radiotherapy, which contrasts with previous studies results and needs to be further investigated [26].

To our knowledge, this study is the first to provide estimates of ASP burden related to breast cancer in Zambia, Uganda, and Namibia. Major strengths of this study were its multi-country design and large sample size; the use of a common protocol and data collection system for all four study sites, and of mHealth technology for study management, data collection and active follow-up of the participants. With the exception of Zambia, where an interruption of follow-up led to irreversible losses to follow-up, mHealth has ensured very few losses to follow-up in ABC-DO, and timely death notification [16]. The use of the validated EORTC-QLQ-Br23 questionnaire, a quality-of-life questionnaire with a special module for breast cancer patients, allowed us to capture accurate, affordable, and reproducible measures of ASP experienced by women in our cohort. Our study demonstrated that this questionnaire can be used to monitor breast cancer survivors across different countries and ethnicities in SSA, similarly to what has been shown in HICs [17]. Our large study population and relatively high number of arm and shoulder outcomes enabled us to obtain reliable and accurate estimates of ASP burden, and to study their determinants in the Sub-Saharan setting.

Our study population may not be representative of all breast cancer patients in SSA and the frequency of ASP. This is because recruitment was hospital-based, and some breast cancer cases may not seek care or may not be referred. However, hospital settings were tertiary centres, which is often the only treatment centre in the country and participation rate was very high (about 99%). After the baseline interview, at each 3-month follow-up contact, women were asked to report whether they had experienced ASP in the previous week. At the time of the first EORTC-QLQ-Br23 questionnaire, some women had already experienced an ASP. Therefore, our estimates are a proxy for incidence of ASP in this population because the baseline rates of ASP could not be determined in our population and those that occurred in between the 3-month follow-up interviews may have been missed. Moreover, EORTC-QLQ-Br23 questions did not specify the side affected by ASP. In light of these considerations, we would advise future studies focussed on ASPs to (1) perform clinical measurements whenever possible; (2) ascertain a time-stamped history of ASPs at the time of diagnosis; (3) for each of the above, separately ascertain ASPs for the affected and contralateral breast and, in parallel, obtain laterality information for all treatments administered. As compared to objective measurement, patients’ self-reports of arm swelling have been shown to have high sensitivity, but only moderate specificity [30], with the resulting false-positives leading to an over-estimation of the frequency of ASP. We improved specificity by only considering moderate to severe self-reported arm symptoms as indicative of ASP, as was done in other studies [5, 18, 19]. Moreover, the use of a validated questionnaire and standardized procedures to collect data on ASP limited the impact of misclassification on the study results. In our cohort, as the vast majority of women who received surgery got a mastectomy and data on axillary management was lacking, we were not able to analyse the impact of breast surgery type or axillary management technique on occurrence of ASP.

This study highlights the high frequency of ASP following a breast cancer diagnosis in SSA as well as the presence of marked differences between countries and, in Namibia, also between ethnic groups. Indeed, the cost of breast cancer-related ASP is not only physical or emotional by lowering a woman’s quality-of-life, but it may also have financial consequences, notably by impacting on a woman’s ability to work, or by engendering higher medical needs and costs (e.g. in the case of repeated infections due to lymphedema) [4, 31‐33]. This may result in dramatic consequences on a woman’s ability to get appropriate care and take care of her family. Thus, identifying modifiable risk factors of ASP that could be targeted by future interventions is crucial to help preventing ASP in SSA. Further research is needed to better understand the impact of treatment on the occurrence of ASP in this setting (e.g. studies with complete treatment data including quality of surgery and after care, chemotherapy administration mode and associated side-effects, studies comparing women’s pain score pre- and post-surgery).

As WHO launches its Global Breast Cancer Initiative in 2021, improving the diagnosis, prevention, and management of ASP in LMICs is important. Breast cancer care and survivorship programmes need to be developed in SSA, and should combine educational, financial, and emotional support components to significantly improve breast cancer patient’s quality-of-life and reduce the burden of ASP [25, 34‐36]. These programmes should address ASP awareness, prevention, detection, and management. Moreover, they would need to reach breast cancer patients, health care professionals and also traditional healers, as these play an important role in cancer care delivery in this setting [37]. Affordable self-management measures should be emphasized and could be implemented in settings where access to care is lacking, and women should have access to physical and decongestive therapies whenever possible. Moreover, downstaging breast cancer is crucial to further reduce ASP burden in SSA, by raising awareness of this disease and by promoting its early detection in the region, especially among underprivileged populations who are the most at risk of late breast cancer diagnosis.